{"id":6806,"date":"2022-06-03T06:07:53","date_gmt":"2022-06-03T06:07:53","guid":{"rendered":"https:\/\/zaratechs.com\/?p=6806"},"modified":"2022-06-03T06:07:53","modified_gmt":"2022-06-03T06:07:53","slug":"hyperlipidemia-drugs-market-trends-scope-size-growth-and-analysis-2022-27","status":"publish","type":"post","link":"https:\/\/zaratechs.com\/hyperlipidemia-drugs-market-trends-scope-size-growth-and-analysis-2022-27\/","title":{"rendered":"Hyperlipidemia Drugs Market Trends, Scope, Size, Growth And Analysis 2022-27"},"content":{"rendered":"\n

According to the latest report by IMARC Group \u201cHyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027<\/strong>\u201c, The global hyperlipidemia drugs market reached a value of US$ 21.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 24.8 Billion by 2027, exhibiting a CAGR of 2.17% during 2022-2027.<\/p>\n\n\n\n

Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood. It is a common type of dyslipidemia that can be inherited or result from an unhealthy lifestyle and poor diet. The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs). Hyperlipidemia can be detected by performing a blood test called a lipid panel or lipid profile. Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle. Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver. They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.<\/p>\n\n\n\n

Request for a free sample copy of this report: <\/strong>https:\/\/www.imarcgroup.com\/hyperlipidemia-drugs-market\/requestsample<\/a><\/p>\n\n\n\n

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.<\/strong><\/p>\n\n\n\n

Market Trends:<\/strong><\/p>\n\n\n\n

The global hyperlipidemia drugs market is primarily driven by the increasing awareness regarding the associated risks of CVDs and high cholesterol. Governments are introducing new guidelines redefining at-risk patient groups and recommending the use of anti-hyperlipidemic to lower the risk of these diseases. In addition to this, the upcoming patent expiration has resulted in the genericization of statin and cholesterol absorption inhibitors, which is significantly augmenting the market growth. Furthermore, the launch of innovative products, such as the development of novel drugs, which offer improved efficacy and safety profile, is positively impacting the market across the globe. Moreover, there has been extensive research and development (R&D) activities for developing innovative drugs. On account of these factors, the market is expected to exhibit a CAGR of 2% during the forecast period (2021-2026).<\/p>\n\n\n\n

Breakup by Drug Type:<\/strong><\/p>\n\n\n\n